Developing an intelligent system for diagnosing nasopharyngeal carcinoma
To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
This study is testing a new smart system that uses artificial intelligence to help doctors find early signs of nasopharyngeal carcinoma in patients who are at high risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Guangzhou, Guangdong and 2 other locations) |
| Trial ID | NCT04547673 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and validate an intelligent diagnostic system using artificial intelligence to detect early nasopharyngeal carcinoma (NPC) through nasoendoscopic examination. The approach utilizes both white light imaging and narrow-band imaging techniques to enhance the detection of diverse nasopharyngeal lesions. By focusing on a population with a high incidence of NPC, the study seeks to improve diagnostic accuracy and patient outcomes through a novel computer-aided diagnosis system.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years of age who are at risk for nasopharyngeal carcinoma.
Not a fit: Patients with contraindications such as coagulation dysfunction or drug allergies may not benefit from this study.
Why it matters
Potential benefit: If successful, this system could lead to earlier detection of nasopharyngeal carcinoma, improving treatment outcomes for patients.
How similar studies have performed: Other studies utilizing artificial intelligence for cancer detection have shown promising results, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Older than 18 years of age Exclusion Criteria: * Refuse to sign the informed consent statement * Patients who have contraindications, e.g. coagulation dysfunction, drug allergy.
Where this trial is running
Guangzhou, Guangdong and 2 other locations
- First Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
- Sun Yat-Sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
- Kiang Wu Hospital — Macao, Macao, China (Recruiting)
Study contacts
- Study coordinator: Yihui Wen, Ph.D
- Email: wenyihui@mail.sysu.edu.cn
- Phone: +86-13480200660
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.